News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alnylam Pharmaceuticals (ALNY) Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Rnai-Mediating, Double-Stranded Molecules Of 19 To 52 Nucleotides In Length


8/27/2014 10:38:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl et al. patent application 12/591,829. The ’829 patent application includes newly allowed claims directed to compositions comprising a double-stranded molecule of between 19 and 52 nucleotides in each strand with various end configurations, including a so-called “3’ overhang” on the antisense strand. As such, the newly allowed patent application broadly covers small interfering RNA, or “siRNA,” molecules of various designs including so-called “dicer substrate” RNAi triggers. Moreover, the claims also cover double-stranded RNAi-mediating molecules with one or more nucleotide analogue such as “unlocked nucleobase analogs,” or “UNAs,” amongst other naturally or non-naturally occurring nucleotide analogues.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES